Proficio Capital Partners LLC purchased a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 11,282 shares of the specialty pharmaceutical company's stock, valued at approximately $408,000.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in SUPN. Charles Schwab Investment Management Inc. increased its holdings in shares of Supernus Pharmaceuticals by 14.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company's stock valued at $22,212,000 after purchasing an additional 91,354 shares in the last quarter. Geode Capital Management LLC boosted its position in Supernus Pharmaceuticals by 5.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company's stock valued at $46,218,000 after buying an additional 74,438 shares during the period. JPMorgan Chase & Co. increased its position in shares of Supernus Pharmaceuticals by 40.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company's stock valued at $7,901,000 after purchasing an additional 73,118 shares during the last quarter. Burney Co. raised its holdings in Supernus Pharmaceuticals by 603.4% during the fourth quarter. Burney Co. now owns 83,152 shares of the specialty pharmaceutical company's stock worth $3,007,000 after purchasing an additional 71,331 shares in the last quarter. Finally, Wedge Capital Management L L P NC acquired a new position in Supernus Pharmaceuticals during the fourth quarter worth approximately $1,928,000.
Insiders Place Their Bets
In related news, SVP Jonathan Rubin sold 927 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the sale, the vice president now owns 10,149 shares of the company's stock, valued at $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 11,104 shares of company stock worth $440,263 over the last ninety days. Company insiders own 9.30% of the company's stock.
Supernus Pharmaceuticals Price Performance
Shares of SUPN traded down $0.13 during trading hours on Friday, reaching $32.29. 245,026 shares of the company's stock traded hands, compared to its average volume of 478,479. The business's fifty day simple moving average is $35.26 and its two-hundred day simple moving average is $35.02. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of 30.18 and a beta of 0.83. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $40.28.
Wall Street Analyst Weigh In
Several research analysts recently issued reports on SUPN shares. StockNews.com cut shares of Supernus Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday. Cantor Fitzgerald reissued a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.
Get Our Latest Analysis on SUPN
About Supernus Pharmaceuticals
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Featured Articles
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
